TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ondine Biomedical, Inc. ( (GB:OBI) ) has provided an update.
Ondine Biomedical Inc. has announced the grant of 300,000 options to a key consultant, allowing them to subscribe for new common shares at an exercise price of 15.50 pence. These options will vest over three years and can be exercised within eight years, contributing to a total of 18,863,334 options outstanding, which represents 3.64% of the company’s current issued share capital.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, also known as photodisinfection. The company has a range of investigational products based on its proprietary technology, including a nasal photodisinfection system that is approved in Canada, Europe, and other countries under the name Steriwave®. Ondine is also pursuing regulatory approval in the US, where it has received special designations from the FDA.
Average Trading Volume: 390,174
Technical Sentiment Signal: Buy
Current Market Cap: £80.35M
See more data about OBI stock on TipRanks’ Stock Analysis page.